Par Pharmaceutical Companies, Inc. – Value – Zacks Rank Buy
Source: http://www.zacks.com/commentary/11063/Par+Pharmaceutical+Companies%2C+Inc.+-+Value+-+Zacks+Rank+BuyPosted on Tuesday, June 2nd, 2009 | In Market Commentary, Stocks to Watch
Par Pharmaceutical Companies, Inc. (PRX), the generic drug manufacturer, saw revenue grow 32% as sales popped for Metroprolol, the generic version of angina drug Toprol. The company’s surprise of 81.48% had analysts scrambling to raise estimates. PRX is trading with a PEG ratio of just 0.79.
Company Description
Par Pharmaceutical manufactures generic drugs and branded pharmaceuticals for the specialty markets. The company ranks among the top ten in generic drug sales in the United States.
The branded division, Strativa Pharmaceuticals, was launched in 2005 and has licensed 4 proprietary drugs that are in development.
Revenue Surged 32% in the First Quarter
On May 6, Par reported first quarter results which easily surprised on Wall Street estimates by 81.48%. Adjusted earnings per share were 49 cents compared to 17 cents in the year ago period. Analysts were expecting just 27 cents.
Revenue grew 32% to $204 million from $154.9 million in the year ago period. Growth was fueled by a 127% increase in sales of Metroprolol, a generic version of Toprol XL, which treats angina.
Par became the authorized generic distributor for Toprol, which was developed by AstraZeneca, in the first quarter. Gains in three other generic drugs offset declines in fluticasone and Megace ES.
Consensus Estimates Jump
Given the far better-than-expected second quarter results, covering analysts have been raising estimates for the second quarter and the full-year.
Second-quarter consensus estimates rose 65% to 43 cents from 26 cents in the last 30 days with 7 out of 8 covering analysts raising during that time.
Full-year consensus estimates jumped 44% to $1.31 from 91 cents in the last month, also with 7 out of 8 analysts raising estimates.
Value Fundamentals
Par Pharmaceuticals is a Zacks #1 Rank (strong buy) stock. It has attractive value characteristics. Its forward P/E is 11.9 while its price-to-book is 1.09. Analysts expect 5-year earnings growth of 13%.
Last 5 posts by Tracey Ryniec
- Cooper Tire & Rubber Company - Value - Zacks Rank Buy - November 20th, 2009
- Ameriprise Financial Inc. - Value - Zacks Rank Buy - November 19th, 2009
- 3 Dirt Cheap Stocks - Investment Ideas - November 19th, 2009
- DryShips Inc. - Value - Zacks Rank Buy - November 18th, 2009
- Ctrip.com International Limited - Aggressive Growth - Zacks Rank Buy - November 17th, 2009
angina, Astrazeneca, authorized generic distributor;, cent;, generic drug manufacturer, generic-drugs, Market Commentary, Megace ES;, Par Pharmaceutical Companies Inc.;, Par Pharmaceuticals;, Pharmaceuticals, Stocks to Watch, Strativa Pharmaceuticals;, Toprol;, United States, USD, Value - Zacks Rank Buy Par Pharmaceutical Companies Inc.;, Zacks Market Commentaries
 About Tracey Ryniec (http://www.zacks.com/)
Tracey Ryniec is an Editor at Zacks Investment Research who covers the Value Stock for the Zacks Rank Buys and Timely Buy of the Week. |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.